Advertisement

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study

  • Hiroe Nagaike
  • Makoto OharaEmail author
  • Yo Kohata
  • Munenori Hiromura
  • Masako Tomoyasu
  • Michiya Takada
  • Takeshi Yamamoto
  • Toshiyuki Hayashi
  • Tomoyasu Fukui
  • Tsutomu Hirano
Open Access
Original Research
  • 586 Downloads

Abstract

Introduction

To compare the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM).

Methods

Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks. The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI). The secondary end points were changes in body weight (BW), glucose variability, diabetes treatment satisfaction questionnaire (DTSQ) score, and eating behavior.

Results

There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment. Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment. However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating. The DTSQ score for “convenience” improved in the dulaglutide group. No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.

Conclusion

We showed that once-weekly dulaglutide was comparable to once-daily liraglutide in terms of oxidative stress and endothelial function. Switching from liraglutide to dulaglutide improved convenience by decreasing the number of injections without deteriorating glucose metabolism.

Trial Registration

This trial was registered with the University Hospital Medical Information Network (UMIN no. 000034353) on 10 October 2018.

Keywords

Dulaglutide Endothelial function Glucose variability Oxidative stress Type 2 diabetes mellitus 

Introduction

Type 2 diabetes mellitus (T2DM) is a major cause of atherosclerosis and is related to vascular complications [1], while being a major cause of mortality [2]. Therefore, it is important to prevent the development and progression of diabetic complications. A recent study revealed that the use of a glucose-like peptide 1 (GLP-1) receptor agonist (RA) reduces the risk of cardiovascular events in patients with T2DM who are at a high risk of cardiovascular events [3, 4].

It has been reported that arteriosclerosis in T2DM patients is caused by an increase in oxidative stress due to glucose variability, which results in vascular endothelial dysfunction [5]. We also reported that the presence of diacron-reactive oxygen metabolites (d-ROMs), a surrogate marker of oxidative stress, was associated with daily glucose variability in T2DM patients [6]. Torimoto et al. reported that the reactive hyperemia index (RHI), a marker of vascular endothelial function, as assessed with the EndoPAT 2000® system (Itamar Medical, Ltd., Caesarea, Israel), was correlated with daily glucose variability [7]. Therefore, it is considered important to reduce oxidative stress and protect vascular endothelial function for the treatment of T2DM [8].

Recently, our group demonstrated that reducing the frequency of injections, with basal-bolus insulin therapy switched to liraglutide plus basal insulin, improved treatment satisfaction compared with basal-bolus insulin therapy [9].

Dulaglutide derived from human GLP-1 is a once-weekly GLP-1 RA approved in Japan at a dosage of 0.75 mg [10]. In a phase III study, once-weekly dulaglutide (0.75 mg) was not inferior to liraglutide (0.9 mg, the highest available dosage in Japan) for the control of changes in glycated hemoglobin (HbA1c) levels [11]. A recent study reported that patient satisfaction with once-weekly dulaglutide was superior to that of once-daily liraglutide [12]. However, so far no study has demonstrated the differences between the effects of dulaglutide and liraglutide on glucose variability, as calculated by continuous glucose monitoring (CGM). In addition, there has been no report to date on the suppression of oxidative stress and protective effects on vascular endothelial function in patients with T2DM with the use of once-weekly dulaglutide and once-daily liraglutide.

Therefore, the aim of the present study was to investigate and compare the effects of once-weekly dulaglutide and once-daily liraglutide for 24 weeks on oxidative stress, endothelial function, glucose variability as assessed by CGM, treatment satisfaction, and eating behavior.

Methods

Subjects

Twenty-two patients with T2DM who received liraglutide for at least 12 weeks were randomized to either continue liraglutide (n = 11) or dulaglutide (n = 11) for 24 weeks. The study was conducted from September 2016 to March 2018. The inclusion criteria were as follows: (1) a diagnosis of T2DM, (2) age ≥ 20 years, (3) HbA1c ≥ 6.5%, and (4) treatment with liraglutide for ≥ 12 weeks. The exclusion criteria were as follows: (1) the use of steroids or anti-inflammatory drugs, (2) diabetic ketosis and coma within 3 months before the start of the study, (3) severe infection, (4) severe trauma or malignancy, (5) an estimated glomerular filtration rate of < 30 ml/min/1.73 m2, according to the Cockcroft-Gault formula, (6) recent surgery, (7) severe liver dysfunction, and (8) pregnancy.

Study Design

Supplementary Figure S1 summarizes the protocol of this open-label, prospective, and randomized study. Patients were randomly divided into two groups: one that continued treatment with liraglutide and a second that was switched to treatment with dulaglutide. The number of patients withdrawing because of adverse events was similar between both treatment groups (Supplementary Figure S2). At baseline and 24 weeks after continuation of liraglutide or switching to dulaglutide, the following clinical and laboratory parameters were measured for all the patients in both groups before breakfast on day 1 of CGM: body weight (BW), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), estimated glomerular filtration rate, blood pressure, fasting plasma glucose (FPG), and HbA1c content. Plasma oxidant capacity against N,N-diethylparaphenylenediamine was measured using the d-ROMs test on day 1. CGM was performed for 72 h. The parameters of glucose variability, such as mean glucose level (MGL), percentage coefficient of variation for glucose (%CV), mean amplitude of glycemic excursion (MAGE), and the mean of daily differences (MODD) in glucose levels were measured on days 2 and 3. Peripheral vascular arterial tonometry (PAT), as measured with the EndoPAT 2000® system, provides noninvasive assessment of the RHI, a marker of vascular endothelial function and vascular health [13]. PAT was measured at baseline and 24 weeks after the start of the study. Because the RHI has a heteroscedastic error structure, L_RHI (a natural logarithm transformation) was used in all the analyses. All the clinical data (i.e., age, sex, smoking habit, and duration of diabetes in years) were retrieved from medical records. No changes were made to the type and dosage of oral hypoglycemic agents, insulin, angiotensin II receptor blocker, angiotensin-converting enzyme inhibitor, and statins during the study period to avoid possible influences on oxidative stress and endothelial function. All the drugs had been prescribed for at least 12 weeks before starting the study.

The Ethics Committee of the Showa University School of Medicine approved the study protocol. The study protocol is in compliance with the Declaration of Helsinki and current legal regulations in Japan. All procedures are in accordance with the ethical standards of the institutional and national committees responsible for human experimentation and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients before being included in the study.

Procedures and Measurements

For each patient, a MiniMed iPro2 CGM system (Medtronic Inc., Northridge, CA, USA) was inserted subcutaneously on day 1 and removed on day 4. To avoid inaccurate results, glucose variability was calculated only on days 2 and 3. Venous blood samples were drawn for laboratory measurements on day 1 before breakfast. All the patients received a weight-maintaining diet (25–30 kcal/kg ideal BW). Glucose variability was calculated using the CGM data. The MGL and incidences of hypoglycemia (percent of h under 70 mg/dl in 24 h) were measured from the data recorded during CGM and adjusted for self-monitored blood glucose. The MAGE [14] was calculated to assess glucose variability. The MODD [15] was calculated as the mean of the absolute difference between corresponding glucose values on days 2 and 3. The percentage of CV was calculated using the coefficient of variation obtained by dividing the standard deviation by the MGL and multiplying by 100 [16].

Laboratory Measurements

Oxidative stress was measured using the d-ROMs test [17] and a dedicated photometer (F.R.E.E. System; imported by LTD Tokyo from Diacron International s.r.l., Grosseto, Italy), as reported previously [18]. According to the Wismerll kinetic procedure, the change in absorbance/min was expressed as arbitrary units after correction (U.CARR, where 1 U.CARR = the oxidant capacity of a 0.08 mg/dl of H2O2 solution; normal range, 250–300 U.CARR). The intra- and inter-assay coefficients of variation were 2.1% and 3.1%, respectively. An automated analyzer (BM6070; Japan Electron Optics Laboratory Co., Ltd., Tokyo, Japan) was used to measure serum total cholesterol, LDL-C, HDL-C, TG, and creatinine levels. Plasma glucose was measured by the glucose oxidase method, and HbA1c was measured by high-performance liquid chromatography [19].

Diabetes Treatment Satisfaction and Eating Behavior

Treatment satisfaction was assessed using a validated self-administered questionnaire, the diabetes treatment satisfaction questionnaire (DTSQ), at baseline and 24 weeks after the start of the study [20, 21]. The DTSQ is used to assess treatment satisfaction according to eight items that are scored on a 7-point Likert scale from 0 (very dissatisfied) to 6 (very satisfied). The total score was calculated as the sum of scores for the following six satisfaction items: “current treatment,” “convenience,” “flexibility,” “understanding,” “recommend,” and “continue,” yielding a total score from 0 to 36. The other two items of “perceived frequency of hyperglycemia” and “perceived frequency of hypoglycemia” were treated individually.

Eating behavior was assessed using the questionnaire of The Guideline for Obesity, issued by the Japan Society for the Study of Obesity, at baseline and 24 weeks after the start of the study. As reported previously [22, 23], this questionnaire consists of 55 questions of seven major scales, as follows: (1) recognition of weight and constitution (e.g., “Do you think it is easier for you to gain weight than others?” and “Do you think you gain weight because of less exercise?”), (2) external eating behavior (e.g., “If food smells and looks good, do you eat more than usual?,” “If you walk past a supermarket, do you have a desire to buy something delicious?,” and “If you see others eating, do you also have the desire to eat?”), (3) emotional eating behavior (e.g., “Do you have a desire to eat when you are irritated?” and “Do you have a desire to eat when you have nothing to do?”), (4) sense of hunger (e.g., “Do you get irritated when you feel hungry?” and “Do you often regret that you have eaten a lot of food?”), (5) eating style (e.g., “Do you eat quickly?” and “Are you known to eat a lot of food?”), (6) food preference (e.g., “Do you often snack on bread?,” “Do you like meat?,” and “Do you like noodles?”), and (7) regularity of eating habits (e.g., “Is your dinner time too late at night?” and “Do you gain body weight during holidays?”). All the items were rated on a four-point scale ranging from 1 (seldom) to 4 (very often).

End Points and Assessments

The primary end points were d-ROMs and L_RHI change from baseline after 24 weeks of treatment. The secondary end points were changes in BW, glucose variability, lipid metabolism, DTSQ score, and eating behavior score.

Statistical Analysis

All normally distributed continuous data sets, as determined by the Shapiro-Wilk test, are expressed as the mean ± standard deviation. Differences in continuous variables between the liraglutide and dulaglutide groups at baseline and after treatment were evaluated using the independent sample t test or Mann-Whitney U test. The chi-square test was used to compare categorical variables. Pearson’s simple linear regression was used to calculate the correlation coefficients. A probability p value < 0.05 was considered statistically significant. IBM SPSS, version 22, for Windows (IBM Corp., Armonk, NY, USA) was used to perform the analyses.

Results

Clinical Characteristics

Of the 27 participants who were enrolled, 22 (81.5%) had completed the protocol. Table 1 shows the clinical and laboratory characteristics of the 22 participants (11 participants in the dulaglutide and liraglutide groups each). For the dulaglutide group, the mean age, body mass index, duration of diabetes, and HbA1c content were 69.2 ± 9.1 years, 26.7 ± 4.4 kg/m2, 14.5 ± 8.9 years, and 7.1% ± 0.5%, respectively. The baseline characteristics of the patients in the liraglutide group were similar to those in the dulaglutide group. The values of FPG, MGL, MAGE, MODD, %CV, and hypoglycemia were similar in both groups. Oxidative stress, as measured by the d-ROMs test, and endothelial function, as measured by L_RHI, were similar between groups.
Table 1

Clinical characteristics of subject at baseline

 

Dulaglutide (n = 11)

Liraglutide (n = 11)

p value

Age (years)

69.2 ± 9.1

67.8 ± 9.5

0.718

Sex (male)

9 (81.8)

4 (36.4)

0.076

Body weight (kg)

68.3 ± 13.4

63.4 ± 12.9

0.401

BMI (kg/m2)

26.7 ± 4.4

25.9 ± 3.6

0.932

Duration of diabetes (years)

14.5 ± 8.9

13.7 ± 8.2

0.844

Hypertension

10 (90.9)

10 (90.9)

1.000

Dyslipidemia

11 (100)

10 (90.9)

0.748

Blood pressure (mmHg)

   

 Systolic

137.5 ± 17.5

138.5 ± 19.1

0.938

 Diastolic

78.0 ± 12.0

80.0 ± 13.7

0.768

HDL-C (mg/dl)

48.7 ± 9.6

50.1 ± 11.5

0.970

LDL-C (mg/dl)

84.8 ± 21.2

81.5 ± 21.4

0.617

Triglyceride (mg/dl)

106.8 ± 23.5

112.5 ± 41.0

0.318

eGFR (ml/min/1.73 m2)

71.5 ± 18.0

76.6 ± 19.2

0.900

FPG (mg/dl)

141.5 ± 27.1

157.0 ± 58.7

0.156

HbA1c (%)

7.1 ± 0.5

7.2 ± 0.5

0.222

Mean glucose level (mg/dl)

159.2 ± 25.8

149.5 ± 22.9

0.727

Markers of glucose variability

   

 MAGE (mg/dl)

105.2 ± 23.4

110.4 ± 21.9

0.483

 MODD (mg/dl)

27.5 ± 8.1

32.6 ± 14.1

0.235

 %CV (mg/dl)

22.6 ± 4.7

25.3 ± 3.4

0.776

FCPR (ng/ml)

2.6 ± 1.3

1.7 ± 0.9

0.714

d-ROMs (U.CARR)

288.1 ± 35.5

309.5 ± 44.3

0.333

L_RHI

0.48 ± 0.31

0.34 ± 0.13

0.268

Macroangiopathy

5 (45.5)

2 (18.2)

0.300

Neuropathy

8 (72.7)

10 (100.0)

0.300

Nephropathy

5 (45.5)

7 (63.6)

0.478

Retinopathy

3 (27.3)

5 (45.5)

0.478

Antidiabetic drugs

   

 Sulfonylurea

1 (9.1)

0 (0.0)

0.748

 Glinide

0 (0.0)

1 (9.1)

0.748

 Thiazolidine

1 (9.1)

1 (9.1)

1.000

 α-Glucosidase inhibitors

5 (45.5)

1 (9.1)

0.151

 Metformin

5 (45.5)

5 (45.5)

1.000

 SGLT2 inhibitors

1 (9.1)

2 (18.2)

0.748

 Insulin

3 (27.3)

8 (72.7)

0.076

Antihypertensive drugs

   

 ARB or ACEi

9 (81.8)

7 (63.6)

0.478

 Calcium channel blocker

8 (72.7)

7 (63.6)

0.748

 α-Blocker

1 (9.1)

0 (0.0)

0.748

 β-Blocker

4 (36.4)

1 (9.1)

0.300

Antihyperlipidemic drugs

   

 Statins

10 (90.9)

9 (81.8)

0.748

DTSQ scores

   

 1. Current treatment

5.36 ± 0.67

4.82 ± 1.08

0.223

 2. Hyperglycemia

3.36 ± 2.01

2.45 ± 1.92

0.288

 3. Hypoglycemia

1.18 ± 1.66

1.73 ± 1.79

0.406

 4. Convenience

4.55 ± 1.04

4.09 ± 1.45

0.476

 5. Flexibility

4.27 ± 1.35

4.27 ± 1.42

0.946

 6. Understanding

4.64 ± 1.12

4.27 ± 1.27

0.424

 7. Recommend

4.64 ± 1.29

4.09 ± 1.58

0.459

 8. Continue

5.00 ± 1.10

4.73 ± 1.27

0.631

 Total score of 2 and 3

4.55 ± 3.05

4.18 ± 2.71

0.617

 Total score of 1, 4, 5, 6, 7, and 8

28.45 ± 3.93

26.27 ± 7.07

0.644

Eating behavior

   

 Total (%)

36.31 ± 19.13

39.16 ± 20.67

0.646

Data are expressed as the mean ± standard deviation

1 U.CARR (arbitrary unit) = oxidant capacity of 0.08 mg/dl H2O2 solution

%CV percentage coefficient of variation for glucose, ARB angiotensin II receptor blocker, ACE angiotensin-converting enzyme inhibitor, d-ROMs diacron-reactive oxygen metabolites, eGFR estimated glomerular filtration rate, FCPR fasting C-peptide, FPG fasting plasma glucose, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, L_RHI the natural logarithmic scale reactive hyperemia index, MAGE mean amplitude of glycemic excursions, MODD mean of daily difference of blood glucose

Effects of 24 weeks of Dulaglutide and Liraglutide on Clinical and Biochemical Parameters

As Fig. 1 and Table 2 show, there were no significant differences in d-ROMs and L-RHI from baseline to 24 weeks or in the degree of change in d-ROMs and L-RHI between the dulaglutide and liraglutide groups.
Fig. 1

Comparison of individual change of d-ROMs and L_RHI before and after treatment with dulaglutide versus liraglutide

Table 2

Comparison of clinical and biochemical parameters at baseline and 24 weeks

 

Dulaglutide

Liraglutide

 
 

Baseline

24 weeks

p1 value

Baseline

24 weeks

p1 value

p2 value

Body weight (kg)

68.3 ± 13.4

69.1 ± 14.0

0.898

63.4 ± 12.9

64.4 ± 13.8

0.857

0.949

Systolic blood pressure (mmHg)

137.5 ± 17.5

136.8 ± 20.2

0.938

138.5 ± 19.1

131.6 ± 21.1

0.436

0.478

Diastolic blood pressure (mmHg)

78.0 ± 12.0

79.7 ± 14.9

0.768

79.7 ± 14.9

76.1 ± 13.7

0.511

0.151

HDL-C (mg/dl)

48.7 ± 9.6

50.1 ± 11.5

0.766

50.1 ± 11.5

49.8 ± 12.2

0.970

0.847

LDL-C (mg/dl)

84.8 ± 21.2

90.0 ± 24.0

0.598

81.5 ± 21.4

76.4 ± 25.4

0.617

0.040a

TG (mg/dl)

106.8 ± 23.5

133.2 ± 80.3

0.461

112.5 ± 41.0

140.2 ± 79.0

0.318

0.748

eGFR (ml/min/1.73 m2)

71.5 ± 18.0

69.0 ± 14.2

0.722

76.6 ± 19.2

75.6 ± 18.7

0.900

0.949

FPG (mg/dl)

141.5 ± 27.1

132.8 ± 33.4

0.509

128.3 ± 23.6

157.0 ± 58.7

0.156

0.101

HbA1c (%)

7.1 ± 0.5

7.1 ± 0.6

0.970

7.2 ± 0.5

7.6 ± 0.9

0.222

0.116

Mean glucose level (mg/dl)

159.2 ± 25.8

155.8 ± 18.8

0.727

149.5 ± 22.9

177.0 ± 35.9

0.048a

0.023a

MAGE (mg/dl)

105.2 ± 23.4

97.4 ± 27.8

0.483

109.9 ± 21.9

136.9 ± 42.7

0.087

0.034a

MODD (mg/dl)

27.5 ± 8.1

33.0 ± 12.4

0.235

32.6 ± 14.1

43.1 ± 22.6

0.205

0.562

Hour of under 70 mg/dl

(%24 h)

0.13 ± 0.42

0.35 ± 1.00

0.545

0.09 ± 0.32

0.16 ± 0.49

0.89

0.687

FCPR (ng/ml)

2.6 ± 1.3

2.4 ± 1.2

0.714

1.7 ± 0.9

2.2 ± 1.1

0.277

0.365

d-ROMs (U.CARR)

288.1 ± 35.5

305.1 ± 44.7

0.333

309.5 ± 44.3

333.4 ± 48.9

0.244

0.562

L_RHI

0.48 ± 0.31

0.52 ± 0.41

0.896

0.34 ± 0.13

0.36 ± 0.28

0.554

0.758

Data are expressed as the mean ± standard deviation

(1) p1 value for the intragroup comparison (pre- vs. post-treatment values in the dulaglutide or liraglutide group; ap < 0.05)

(2) p2 value for the intergroup comparison (dulaglutide vs. liraglutide group in the changes from pre- to post-treatment; ap < 0.05)

%CV percentage coefficient of variation for glucose, d-ROMs diacron-reactive oxygen metabolites, eGFR estimated glomerular filtration rate, FCPR fasting C-peptide, FPG fasting plasma glucose, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, L_RHI the natural logarithmic scale reactive hyperemia index, LDL-C low-density lipoprotein cholesterol, MAGE mean amplitude of glycemic excursions, MODD mean of daily difference of blood glucose

Table 2 summarizes the general clinical and biochemical parameters. After 24 weeks of treatment, there were no significant differences in the changes from pre- to post-treatment of clinical and biochemical parameters, with the exception of glucose metabolism, between the dulaglutide and liraglutide groups.

Although there were no significant changes in BW, blood pressure, kidney function, FPG, HbA1c, and FCPR in either group, the change of LDL-C was significantly improved in the liraglutide group compared with the dulaglutide group (5.18 ± 8.86 vs. − 5.09 ± 11.36, respectively, p = 0.040).

Figure 2 shows the 24-h blood glucose profiles by CGM. There were no significant differences in the change of MODD and  %CV between the dulaglutide and liraglutide groups (5.50 ± 10.40 vs. 11.03 ± 22.91, p = 0.562; − 0.73 ± 3.33 vs. 2.07 ± 8.04, p = 0.300, respectively). The dulaglutide group was superior to the liraglutide group in terms of the changes in MGL and MAGE. In particular, regarding the changes in MGL and MAGE, the dulaglutide group remained unchanged, whereas the liraglutide group showed aggravation. (− 3.41 ± 21.66 vs. 27.45 ± 35.34, p = 0.023; –7.84 ± 26.10 vs. 27.00 ± 48.28, p = 0.034, respectively). There was no significant difference in the frequency of hypoglycemia between the dulaglutide and liraglutide groups.
Fig. 2

Glucose level over 24 h during treatment with dulaglutide versus liraglutide at baseline and 24 weeks

Effects of Dulaglutide and Liraglutide on DTSQ Status Scores and Eating Behavior

Table 3 summarizes the self-reported patient treatment satisfaction, as measured by the DTSQ, and eating behavior at baseline at 24 weeks. After 24 weeks of treatment, the sum of the satisfaction-related DTSQ scores for the items of “current treatment,” “perceived frequency of hypoglycemia,” “flexibility,” “understanding,” “recommend,” and “continue” was unchanged in the dulaglutide and liraglutide groups (from 28.45 ± 3.93 to 30.00 ± 5.60 and from 26.27 ± 7.07 to 26.36 ± 3.98, respectively). In the dulaglutide group, the DTSQ score for “convenience” was significantly improved (from 4.55 ± 1.04 to 5.45 ± 0.93, p = 0.040), while the DTSQ score for “perceived frequency of hyperglycemia” was significantly poorer in the liraglutide group (from 2.45 ± 1.92 to 4.18 ± 1.47, p = 0.040). In addition, the DTSQ score for “perceived frequency of hyperglycemia” significantly improved in the dulaglutide group compared with the other group (− 0.45 ± 2.25 vs. 1.73 ± 1.74, p = 0.034).
Table 3

Effect of dulaglutide and liraglutide on DTSQs and eating behavior

 

Dulaglutide

Liraglutide

 

Baseline

24 weeks

p1 value

Baseline

24 weeks

p1 value

p2 value

DTSQ scores

       

 1. Current treatment

5.36 ± 0.67

5.36 ± 1.21

0.562

4.82 ± 1.08

4.91 ± 0.54

0.898

0.847

 2. Hyperglycemia

3.36 ± 2.01

2.91 ± 1.97

0.606

2.45 ± 1.92

4.18 ± 1.47

0.040a

0.034a

 3. Hypoglycemia

1.18 ± 1.66

1.18 ± 1.60

0.898

1.73 ± 1.79

1.18 ± 1.54

0.478

0.652

 4. Convenience

4.55 ± 1.04

5.45 ± 0.93

0.040a

4.09 ± 1.45

4.36 ± 1.03

0.699

0.171

 5. Flexibility

4.27 ± 1.35

5.09 ± 1.14

0.151

4.27 ± 1.42

4.36 ± 1.03

1.000

0.076

 6. Understanding

4.64 ± 1.12

4.18 ± 1.17

0.365

4.27 ± 1.27

4.36 ± 0.81

1.000

0.217

 7. Recommend

4.64 ± 1.29

4.64 ± 1.03

0.949

4.09 ± 1.58

4.09 ± 1.64

0.949

1.000

 8. Continue

5.00 ± 1.10

5.27 ± 1.19

0.519

4.73 ± 1.27

4.36 ± 1.03

0.365

0.116

 Total score of 2 and 3

4.55 ± 3.05

4.09 ± 3.08

0.699

4.18 ± 2.71

5.36 ± 1.50

0.116

0.217

 Total score of 1, 4, 5, 6, 7, and 8

28.45 ± 3.93

30.00 ± 5.60

0.171

26.27 ± 7.07

26.36 ± 3.98

0.652

0.365

Eating behavior

       

 Total (%)

36.31 ± 19.13

37.11 ± 19.49

0.519

39.16 ± 20.67

39.45 ± 21.05

1.000

0.519

Data are expressed as the mean ± standard deviation

(1) p1 value for the intragroup comparison (pre- vs. post-treatment values in the dulaglutide or liraglutide group; ap < 0.05)

(2) p2 value for the intergroup comparison (changes from pre- to post-treatment in the dulaglutide vs. liraglutide group; ap < 0.05)

After 24 weeks of treatment, the eating behavior scores were unchanged in the dulaglutide and liraglutide groups (from 36.31 ± 19.13 to 37.11 ± 19.49 and from 39.16 ± 20.67 to 39.45 ± 21.05, respectively).

Discussion

To the best of our knowledge, the present study is the first to compare the effects of dulaglutide and liraglutide on oxidative stress, vascular endothelial function, glucose metabolism as measured by CGM, patient satisfaction, and eating behavior. The results demonstrated that patients with T2DM who received liraglutide for at least 12 weeks and then switched to dulaglutide showed in the same effect in d-ROMs and L_RHI despite a decrease in the number of injections from once daily to once weekly. These results also demonstrated that dulaglutide improved glucose metabolism and DTSQ scores by decreasing the number of injections from once daily to once weekly compared with liraglutide.

At 26 weeks of the Japanese phase III clinical trial, dulaglutide was not inferior to liraglutide regarding FPG, BW, and HbA1c content change from baseline [24]; however, at 52 weeks, the use of dulaglutide significantly improved the HbA1c content and postprandial plasma glucose both before and after dinner compared with liraglutide [25]. Moreover, HbA1c content was similar between the dulaglutide and liraglutide groups, and the dulaglutide group was superior to the liraglutide group in terms of MGL and MAGE at 24 weeks (at 24 weeks, MGL and MAGE were maintained in the dulaglutide group but were aggravated in the liraglutide group). However, this result may be due to an imbalance in the randomization process regarding T2DM patients with low levels of C-peptide and those receiving insulin therapy in the liraglutide group compared with the dulaglutide group (FCPR, 1.7 ± 0.92 vs. 2.6 ± 1.3, p = 0.714, and insulin therapy, 72.7% vs. 27.3%, p = 0.076, respectively). Jin et al. reported that fasting C-peptide levels were inversely correlated with diurnal daily glucose variability in T2DM patients receiving insulin therapy [26]. Therefore, switching from liraglutide to dulaglutide seems superior in terms of glucose metabolism and variability.

Our group recently reported that improvements in glucose variability were associated with therapeutic intervention to reduce oxidative stress [27]. However, despite the significant difference in daily glucose variability in this study, there were no significant differences in oxidative stress and vascular endothelial function between the dulaglutide and liraglutide groups. There are several reasons for this conflicting result. One might be the effect of insulin treatment independent of glucose metabolism. It has been reported that the GLP-1 RA has a direct beneficial effect on oxidative stress and endothelial function, independent of its glucose-lowering effect [28]. However, since the GLP-1 RA was used in both groups, an effect independent of glucose metabolism on oxidative stress and endothelial function was unlikely. Importantly, treatment with insulin tended to be higher in the liraglutide group than in the dulaglutide group in this study. Ceriello et al. reported the cumulative beneficial effects of a combination of insulin and GLP-1 RA on hyperglycemia-induced oxidative stress and endothelial function for patients with T2DM [29]. The antioxidant properties of the two drugs have different mechanisms, where insulin reduces free radical production [30], while GLP-1 RA increases intracellular antioxidant defenses [31]. These mechanisms could explain the fact that the use of a GLP-1 RA and insulin treatment affected oxidative stress and vascular endothelial function characteristics independent of glucose metabolism in the present study. Another reason is that glycemic control was relatively good at baseline; therefore, it is possible that HbA1c and glucose variability could not be remarkably improved. In addition, oxidative stress was close to normal by treatment with liraglutide before the start of the study; thus, oxidative stress could not be improved by treatment with dulaglutide, which may have led to this result.

The results of this study showed that the degree of change in LDL-C was significantly improved in the liraglutide group compared with the dulaglutide group. Although GLP-1 RAs are potent and have potentially beneficial effects on LDL-C [32], the reason for this result is unknown. However, it has recently been reported that liraglutide suppressed PCSK9 expression through an HNF1α-dependent mechanism and decreased LDL receptor, possibly via PCSK9-independent pathways in db/db mice [33], which may be related to this result.

In addition to oxidative stress, these results showed additional benefits of switching to dulaglutide from liraglutide on endothelial function, glucose metabolism, and treatment satisfaction. In this study, the total DTSQ scores were similar between the liraglutide and dulaglutide groups. On the other hand, the DTSQ score for the item “hyperglycemia” had significantly increased in the liraglutide continuation group compared with the dulaglutide group. These results were consistent with the significant difference in MGL from pre- to post-treatment in the liraglutide group (149.5 ± 22.9 to 177.0 ± 35.9, respectively). Importantly, our study also showed a significant improvement in convenience from pre- to post-treatment in the dulaglutide group. Recently, Takase et al. reported that switching from liraglutide to dulaglutide improved treatment satisfaction, especially regarding convenience and flexibility [12]. Although the data were not shown, in this study, convenience tended to be inversely correlated with the number of injections (r = − 0.552; p = 0.078). Hence, the improved convenience seems to be due to a decrease in the number of injections. However, because the device used for dulaglutide had easier functionality, it possibly contributed to the improved convenience.

There were several limitations to the present study that should be addressed in future research. First, since the study cohort was relatively small, there was no statistically significant difference in terms of the background characteristics of the patients between the two groups. Second, the study lasted only 24 weeks and was not double blinded; therefore, the durability of these benefits is uncertain. Third, this study involved switching from liraglutide to dulaglutide; thus, there is the possibility that the process of switching itself may have brought about a psychologic advantage. Fourth, the dosages of dulaglutide and liraglutide were relatively small, as each was based on the proper dosage for Japanese patients with T2DM. Fifth, considering that the patients had no residual medicine, we believe that strict adherence to the treatment is possible; however, there are some points that we did evaluate accurately. Finally, to deal with these potential issues, the present findings need to be replicated in a longitudinal observation study with a larger population.

Conclusion

Oxidative stress and endothelial function were comparable between once-weekly dulaglutide and once-daily liraglutide. In addition, switching from liraglutide to dulaglutide improved convenience by decreasing the number of injections without deteriorating glucose metabolism.

Notes

Acknowledgements

We thank the participants of the study. We thank Chihiro Morisoto, Misaki Hirakawa, Sachiko Sakurai, Sachiyo Mitani, Tomomi Horikawa, and Yasue Moroto of the Showa University School of Medicine for clinical support. We also thank Enago (http://www.enago.jp) for the English language review of this article.

Funding

No funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for the authorship of this article, take responsibility for the integrity of the work as a whole, and have provided approval for this version to be published.

Authorship Contributions

MO and HN contributed to the study design, data acquisition, and data analysis and wrote the manuscript. TY, TH, TF, and TH reviewed and edited the manuscript for intellectual content. MO, NH, TH, and TF drafted the manuscript. MO, HN, YK, MH, MT, MT, TY, TH, TF, and TH interpreted the data and critically revised the manuscript. All authors have read and approved the final version of the manuscript.

Disclosures

Tsutomu Hirano has received research funds and lecture fees from Daiichi Sankyo, Eli Lilly, Kowa, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Sanwa Kagaku Kenkyusho, and Takeda. Hiroe Nagaike, Makoto Ohara, Yo Kohata, Munenori Hiromura, Masako Tomoyasu, Michiya Takada, Takeshi Yamamoto, Toshiyuki Hayashi, and Tomoyasu Fukui have nothing to disclose.

Compliance with Ethics Guidelines

The Ethics Committee of the Showa University School of Medicine approved the study protocol. The study protocol is in compliance with the Declaration of Helsinki and current legal regulations in Japan. All procedures are in accordance with the ethical standards of the institutional and national committees responsible for human experimentation and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients before being included in the study.

Data Availability

The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Supplementary material

13300_2018_560_MOESM1_ESM.docx (62 kb)
Supplementary material 1 (DOCX 62 kb)

References

  1. 1.
    Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.  https://doi.org/10.1016/S0140-6736(10)60484-9.CrossRefGoogle Scholar
  2. 2.
    Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes. Diabetes Care. 2005;28:2130–5.  https://doi.org/10.2337/diacare.28.9.2130.CrossRefPubMedGoogle Scholar
  3. 3.
    Marso SP, Daniels GH, Brown-Frandsen K, LEADER Steering Committee, LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.CrossRefGoogle Scholar
  4. 4.
    Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–44.  https://doi.org/10.1056/NEJMoa1607141.CrossRefPubMedGoogle Scholar
  5. 5.
    Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16:125–32.  https://doi.org/10.1002/(SICI)1520-7560(200003/04)16:2%3c125:AID-DMRR90%3e3.0.CO;2-4.CrossRefPubMedGoogle Scholar
  6. 6.
    Ohara M, Fukui T, Ouchi M, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62–70.  https://doi.org/10.1016/j.diabres.2016.09.025.CrossRefPubMedGoogle Scholar
  7. 7.
    Torimoto K, Okada Y, Mori H, Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:1.  https://doi.org/10.1186/1475-2840-12-1.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence. 2016;10:1573–81.  https://doi.org/10.2147/PPA.S107543.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yamamoto S, Hayashi T, Ohara M, et al. Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: a randomized prospective pilot study. Diabetes Res Clin Pract. 2018;140:339–46.  https://doi.org/10.1016/j.diabres.2018.03.032.CrossRefPubMedGoogle Scholar
  10. 10.
    Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocr J. 2015;62:1101–14.  https://doi.org/10.1507/endocrj.EJ15-0401.CrossRefPubMedGoogle Scholar
  11. 11.
    Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17:974–83.  https://doi.org/10.1111/dom.12534.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Takase T, Nakamura A, Yamamoto C, et al. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial. J Diabetes Investig. 2018.  https://doi.org/10.1111/jdi.12906 (Epub ahead of print).
  13. 13.
    Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168–74.  https://doi.org/10.1016/S0002-8703(03)00094-2.CrossRefPubMedGoogle Scholar
  14. 14.
    Service FJ, Molnar GD, Rosevear JW, Ackermann E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644–55.  https://doi.org/10.2337/diab.19.9.644.CrossRefPubMedGoogle Scholar
  15. 15.
    Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342–8.CrossRefGoogle Scholar
  16. 16.
    Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40:832–8.  https://doi.org/10.2337/dc16-1769.CrossRefPubMedGoogle Scholar
  17. 17.
    Gerardi G, Usberti M, Martini G, et al. Plasma total antioxidant capacity in hemodialyzed patients and its relationship to other biomarkers of oxidative stress and lipid peroxidation. Clin Chem Lab Med. 2002;40:104–10.  https://doi.org/10.1515/CCLM.2002.019.CrossRefPubMedGoogle Scholar
  18. 18.
    Cesarone MR, Belcaro G, Carratelli M, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18:127–30.PubMedGoogle Scholar
  19. 19.
    Schnedl WJ, Lahousen T, Wallner SJ, Krause R, Lipp RW. Silent hemoglobin variants and determination of HbA1c with the high resolution program of the HPLC HA-8160 hemoglobin analyzer. Clin Biochem. 2005;38:88–91.  https://doi.org/10.1016/j.clinbiochem.2004.09.016.CrossRefPubMedGoogle Scholar
  20. 20.
    Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990;7:445–51.  https://doi.org/10.1111/j.1464-5491.1990.tb01421.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C, editor. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur: Harwood Academic; 1994. p. 111–32.Google Scholar
  22. 22.
    Inoue K, Maeda N, Kashine S, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:109.  https://doi.org/10.1186/1475-2840-10-109.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lau KK, Wong YK, Chan YH, et al. Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. Cardiovasc Diabetol. 2012;11:101.  https://doi.org/10.1186/1475-2840-11-101.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obed Metab. 2015;17:974–83.  https://doi.org/10.1111/dom.12534.CrossRefGoogle Scholar
  25. 25.
    Odawara M, Miyagawa J, Iwamoto N, Imaoka T, Takamuta T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obed Metab. 2016;18.249–57.  https://doi.org/10.1111/dom.12602.
  26. 26.
    Jin SM, Kim TH, Bae JC, Hur KY, Lee MS, Lee MK. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. Diabetes Res Clin Pract. 2014;104:266–72.  https://doi.org/10.1016/j.diabres.2014.02.003.CrossRefPubMedGoogle Scholar
  27. 27.
    Ohara M, Nagaike H, Goto S, et al. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:253–61.  https://doi.org/10.1016/j.diabres.2018.02.017.CrossRefPubMedGoogle Scholar
  28. 28.
    Ceriello A, Novials A, Ortega E, et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013;36:2346–50.  https://doi.org/10.2337/dc12-2469.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ceriello A, Novials A, Canivell S, et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care. 2014;37:1938–43.  https://doi.org/10.2337/dc13-2618.CrossRefPubMedGoogle Scholar
  30. 30.
    Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009;53:S14–20.  https://doi.org/10.1016/j.jacc.2008.10.038.CrossRefPubMedGoogle Scholar
  31. 31.
    Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010;30:1407–14.  https://doi.org/10.1161/ATVBAHA.110.206425.CrossRefPubMedGoogle Scholar
  32. 32.
    Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275–86.  https://doi.org/10.1185/030079908X253870.CrossRefPubMedGoogle Scholar
  33. 33.
    Yang SH, Xu RX, Cui CJ, et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 2018;17:48.  https://doi.org/10.1186/s12933-018-0689-9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2019

Authors and Affiliations

  • Hiroe Nagaike
    • 1
  • Makoto Ohara
    • 1
    Email author
  • Yo Kohata
    • 1
  • Munenori Hiromura
    • 1
  • Masako Tomoyasu
    • 1
  • Michiya Takada
    • 1
  • Takeshi Yamamoto
    • 1
  • Toshiyuki Hayashi
    • 1
  • Tomoyasu Fukui
    • 1
  • Tsutomu Hirano
    • 1
  1. 1.Division of Diabetes, Metabolism, and Endocrinology, Department of MedicineShowa University School of MedicineTokyoJapan

Personalised recommendations